Quick comparison
| Peptide | Class | Evidence | Status |
|---|---|---|---|
| Selank | Synthetic tuftsin analog (peptide) | Limited | Not FDA-approved, research use only, physician oversight advised |
| Semax | ACTH-fragment peptide | Limited | Not FDA-approved, research use only |
| Oxytocin | Endogenous nonapeptide | Limited | Not FDA-approved for anxiety; endogenous hormone, not a marketed anxiolytic drug |
| DSIP | Neuropeptide | Emerging | Not FDA-approved, research use only |
| Neuropeptide Y | Neuropeptide (endogenous, 36-amino acid) | Emerging | Not administered as a drug; no FDA-approved NPY therapy exists |
The ranking
Selank
Selank is a synthetic analog of tuftsin, a naturally occurring immunomodulatory peptide, originally developed in Russia. It is the most discussed synthetic peptide in anxiety-focused peptide content, with a proposed mechanism involving modulation of GABA, serotonin, dopamine, and enkephalin degradation, described as acting indirectly compared to benzodiazepines’ direct GABA-A receptor activation.
Its ranking here reflects sourcing depth and consistency across commercial and clinical pages, not proven efficacy: the evidence base consists of small-scale Russian human studies (e.g., Zozulia et al. on generalized anxiety disorder and neurasthenia, Medvedev et al. comparing it to phenazepam) that have not been replicated in Western peer-reviewed randomized controlled trials as of 2026.
Claims that it is a safer, non-addictive substitute for benzodiazepines are increasingly walked back by more cautious, recent clinical sources.
Strengths
- Most-researched synthetic anxiolytic peptide in this category, with a proposed multi-neurotransmitter mechanism (GABA, serotonin, dopamine, enkephalin pathways)
- Human observational studies from Russia report anxiolytic effects in generalized anxiety disorder and neurasthenia, and in comparisons with phenazepam
- Frequently described as non-sedating, in contrast to benzodiazepines, though this distinction is not strongly evidenced
Limitations
- No Western peer-reviewed randomized controlled trials are registered on ClinicalTrials.gov or indexed in PubMed as of 2026
- Long-term safety and dependency risk are not well established; claims of "no addictive properties" are considered overstated by more cautious, recent sources
- Listed by the FDA among bulk drug substances (as Selank acetate) presenting significant safety risks for compounding, including immunogenicity and purity concerns
- Best for
- Those curious about non-benzodiazepine anxiolytic mechanisms under medical guidance
- Evidence
- Limited
- Status
- Not FDA-approved, research use only, physician oversight advised
Semax
Semax is a synthetic peptide derived from a fragment of adrenocorticotropic hormone (ACTH), originally developed in Russia. It is described across commercial and clinical-editorial sources as boosting BDNF (brain-derived neurotrophic factor) and modulating dopamine, serotonin, and norepinephrine, mechanisms proposed to underlie mood and anxiety effects.
Unlike Selank, Semax’s anxiety-specific evidence is thinner and less consistently discussed across sources, with most descriptions focused on its neurotrophic and monoamine effects rather than dedicated anxiolytic trials. No Western peer-reviewed randomized controlled trials for anxiety are documented in the research.
It ranks below Selank because its anxiety-specific rationale is less developed, even though its broader mechanism profile is frequently cited.
Strengths
- Proposed BDNF-boosting and monoamine-modulating mechanism cited consistently across sources
- Available in intranasal or subcutaneous forms per commercial sources, allowing flexible research use framing
Limitations
- Evidence for anxiety specifically is thinner and less direct than for Selank
- No Western peer-reviewed RCTs for anxiety identified in the research corpus
- Not FDA-approved; sold as a research-use-only compound with unverified purity risks
- Best for
- Those curious about BDNF/monoamine-linked cognitive-anxiety support under medical supervision
- Evidence
- Limited
- Status
- Not FDA-approved, research use only
Oxytocin
Oxytocin is the most-studied endogenous neuropeptide in the anxiety and social bonding research literature, often called the “love hormone” in commercial framing. Human research findings are mixed and context-dependent, a pattern researchers describe as the “oxytocin paradox,” where effects can vary and sometimes worsen social anxiety rather than improve it.
A 2019 systematic review of intranasal oxytocin studies (De Cagna et al., human research synthesis) found no significant difference in anxiety or depression outcomes compared to control. Given this inconsistent evidence base, oxytocin is best understood as a legitimate research target for understanding anxiety biology rather than a proven or approved therapeutic option.
Strengths
- Most extensively researched neuropeptide relevant to anxiety and social behavior
- Backed by a large body of human research, unlike many synthetic peptides with only animal or anecdotal data
Limitations
- A 2019 systematic review found no significant anxiety benefit from intranasal oxytocin in humans
- Effects are inconsistent and context-dependent, sometimes worsening social anxiety (the "oxytocin paradox")
- Not FDA-approved as an anxiety treatment and not a substitute for evidence-based care
- Best for
- Research interest in social bonding and stress biology, not a treatment substitute
- Evidence
- Limited
- Status
- Not FDA-approved for anxiety; endogenous hormone, not a marketed anxiolytic drug
DSIP
DSIP, or Delta Sleep-Inducing Peptide, is mentioned in consumer-facing sources only in passing, typically described as “linked to stress modulation” or sleep improvement. No source in the research corpus provides mechanism detail, dosing, or study citations of any kind for DSIP, whether animal, in-vitro, or human.
It ranks here because it is treated superficially everywhere it appears, with claims that read as inherited talking points rather than sourced evidence. There is no described mechanism connecting DSIP to anxiety specifically, only a loose association with sleep and stress.
Strengths
- Mentioned across more than one source as connected to stress modulation
- Associated with sleep regulation, which is relevant to anxiety-adjacent symptoms
Limitations
- No mechanism of action detail provided in any source
- No study citations, human or animal, described anywhere in the research
- Not FDA-approved and not evaluated for anxiety specifically
- Best for
- Those curious about sleep-linked stress modulation, not anxiety treatment
- Evidence
- Emerging
- Status
- Not FDA-approved, research use only
Neuropeptide Y
Neuropeptide Y (NPY) is an endogenous neuropeptide described as a stress-resilience or “emotional brake” signal in the nervous system. The strongest data point comes from VA-funded human observational research (Dr. Renu Sah, Cincinnati VA), which found combat veterans with PTSD had significantly lower NPY levels than veterans without PTSD, published in Psychoneuroendocrinology (2014).
A separate NIH-funded human study (Sayed et al. 2017) explored NPY dose-ranging in PTSD. Unlike Selank or Semax, NPY appears in this space as a research biomarker and drug target rather than as a synthetic compound marketed or administered for anxiety.
Strengths
- Backed by human observational data (VA/Cincinnati studies) linking low NPY to PTSD
- Studied via a government-funded research program (VA, NIH), not a commercial peptide vendor
- Represents a biologically plausible, receptor-based mechanism for stress resilience
Limitations
- Not formulated, sold, or administered as an anxiety treatment in this research
- Human evidence is correlational (observational), not interventional efficacy data
- No dosing, delivery method, or safety profile exists because it is not used as a therapy
- Best for
- Understanding stress-resilience biology, not self-treatment
- Evidence
- Emerging
- Status
- Not administered as a drug; no FDA-approved NPY therapy exists
How we picked
Each peptide was ranked by weighing human evidence quality (Western peer-reviewed RCTs versus small regional studies versus biomarker/animal data only), proposed mechanism plausibility, and current regulatory standing.
Selank and Semax rank highest because they have the most anxiety-specific human study data, even though that data is limited to older, small-scale Russian research; oxytocin has the largest research base overall but the most contradictory results; DSIP and NPY are ranked lowest for anxiety specifically because evidence is either superficial (DSIP) or exists only as biomarker/target research rather than treatment data (NPY).
This ranking is not an endorsement of use, and none of these compounds is FDA-approved for anxiety.
Important safety note
Most of these compounds are sold as "research use only" products with limited or no Western human safety data, inconsistent purity, and no established dosing standards. The FDA has flagged peptides like Selank acetate as bulk substances that may present significant safety risks in compounding. Anyone considering these should talk to a qualified clinician first rather than self-administering, and should not use them as a substitute for evidence-based anxiety treatment.
Frequently asked questions
Is any peptide on this list FDA-approved for anxiety?
No. None of these peptides have FDA approval for anxiety or any psychiatric indication. This is consistently stated across clinical and research sources and is the most repeated fact in the field.
Which peptide has the strongest evidence for anxiety?
Selank has the most anxiety-specific human data, though it comes from small Russian studies never replicated in Western peer-reviewed RCTs. Oxytocin is the most-studied overall, but a 2019 systematic review found no significant anxiety benefit.
Can Selank replace my benzodiazepine or SSRI?
No. Clinical sources explicitly warn against stopping prescribed medication in favor of Selank, since abrupt benzodiazepine withdrawal carries its own dangers. Evidence-based treatments like CBT and SSRIs remain the standard of care.
Is oxytocin actually a reliable anxiety treatment?
The evidence is mixed and context-dependent, sometimes called the "oxytocin paradox," where it can worsen social anxiety in some contexts. A 2019 systematic review found no significant difference in anxiety outcomes with intranasal oxytocin.
What is neuropeptide Y and could it become an anxiety treatment?
NPY is linked to stress resilience, and VA research found combat veterans with PTSD have significantly lower NPY levels than those without it. It's currently studied as a biomarker/target, not as an administered anxiety treatment.
Why is DSIP ranked so low despite being marketed for stress and sleep?
Every source treating DSIP does so superficially, with no real mechanism detail or study citations. It's labeled "emerging" because the evidence base is essentially undeveloped compared to Selank or oxytocin.
Are research peptides bought online safe to try?
Products sold as "research use only" are frequently mislabeled, contaminated, or inconsistently dosed, per multiple clinical sources. This label itself is a red flag indicating the product hasn't been evaluated for human safety or efficacy.